Arbutus Biopharma
NASDAQ:ABUSArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
BELLUS Health
NASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Greenwich LifeSciences
NASDAQ:GLSIGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Pharvaris
NASDAQ:PHVSPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Vaccitech
NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.